What is the purpose of this trial?
This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class II and III heart failure patients with 30%≤left ventricular ejection fraction (LVEF)≤35%%, and in particular, for identifying patients who are at low risk for sudden cardiac death and who would not benefit, or may suffer harm, from implantation of an ICD device.
Ages: 18 years and older
Dates: 04/03/2017 - 08/31/2019
Last Updated: 04/07/2017
Study HIC#: 2000020060